Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Theranos Refutes Wall Street Journal Report About Its Blood Testing Technology

PALO ALTO, Calif. – Theranos and its chief, Elizabeth Holmes, called a scathing Wall Street Journal report alleging the company only performs 10 percent of its blood tests on its proprietary technology “factually and scientifically erroneous,” according to a statement on the company website. Theranos said it provided all the necessary information to the Wall […]

Read More »

FDA declines to expand approval of Pfizer arthritis drug

U.S. health regulators declined to approve Pfizer Inc’s oral rheumatoid arthritis drug Xeljanz to treat moderate to severe cases of the scaly skin condition plaque psoriasis, the drugmaker said on Wednesday. Pfizer said it received a so-called complete response letter from the Food and Drug Administration. Such letters typically outline concerns and conditions that must […]

Read More »

‘Health’ supplements send 23,000 to emergency rooms in U.S each year

(Reuters Health) Dietary supplements – those “all natural” products people consume for weight loss, extra energy or to self-treat various conditions – send 23,000 people, many of them children, to the emergency room in the U.S. each year, according to a new estimate. Just over 9 percent require hospitalization. Many patients report heart symptoms. The […]

Read More »

India risks missing boat as biosimilars shake up drug industry

India, which has dominated the generic drugs industry for decades, is falling behind in the race to make copies of complex biotech drugs, which are expected to generate tens of billions of dollars in sales in the coming years.   While Indian firms have launched a few such products on the domestic market, where regulatory […]

Read More »

Stressful jobs tied to small increase in stroke risk

(Reuters Health) – Up to one in four jobs are “high strain,” and people in these lines of work may be at increased risk of stroke, according to a new analysis of past research. Based on studies that included nearly 140,000 participants, researchers found an overall 22 percent higher stroke risk among those in high-strain […]

Read More »

Lilly pill trumps Humira in arthritis study

Eli Lilly and Co’s experimental pill for rheumatoid arthritis proved superior to Abbvie Inc’s leading injectable Humira treatment in a large study, which analysts said could prod them to raise sales forecasts for the medicine. Lilly said on Wednesday it was the first study to show that a once-daily oral treatment was superior to $13 […]

Read More »

Japan’s Astellas looking for more deals to refuel drug pipeline

Japan’s Astellas is seeking more deals to refill its drug pipeline as the pharmaceutical company created through a merger 10 years ago explores opportunities in both established and new therapy areas.   “We’re never satisfied with what we have, so we are looking at strategies to augment the portfolio. Nothing is off the table for […]

Read More »

Sitting For Long Periods Not Bad For Health, University of Exeter Study

New research from the University of Exeter and University College London has challenged claims that sitting for long periods increases the risk of an early death even if you are otherwise physically active. The study, which is published in the International Journal of Epidemiology, followed more than 5000 participants for 16 years (making it one […]

Read More »

Germany’s Merck KGaA scraps unit brands

Germany’s Merck KGaA said it would scrap its divisional brands Merck Serono and Merck Millipore and do business simply as Merck outside North America. In the United States and Canada, where its U.S. namesake Merck & Co Inc holds the rights to the Merck name, the German company will continue to operate as EMD Serono […]

Read More »

Chinese firm says plans to mass produce Ebola vaccine

A Chinese firm plans to mass produce a military-developed vaccine against Ebola, even as the epidemic which killed more than 11,000 people in West Africa beings to fade. Privately held Tianjin CanSino Biotechnology Inc is investing 2 billion yuan ($315.14 million) to build a facility in the northeastern city of Tianjin where it will produce […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom